This study aimed to evaluate the usefulness of ultra-sensitive prostate-specific antigen (PSA) following radical prostatectomy (RP).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Between September, 2003 and March, 2009, a total of 311 prostate cancer patients underwent antegrade RP; following the exclusion of 111 patients due to prior hormonal therapy, 200 patients were finally included in this study. The results of the multivariate analysis identified RP Gleason score, extraprostatic extension, lymph node metastasis and PSA nadir as significant predictors of biochemical failure (P=0.0116, 0.0216, 0.0178 and < 0.0001, respectively) and PSA nadir < 0.008 ng/ml exhibited the highest hazard ratio (HR) [HR=26.34; 95% confidence interval (CI): 7.34-104.69]. After a median follow-up period of 52.2 months, the biochemical failure-free rate in the PSA nadir < 0.008 and ≥0.008 ng/ml groups was 94.3 and 58.8%, respectively, with a statistically significant difference according to the log-rank test (P< 0.001). In the multivariate analysis, statistically significant differences were observed only in pathological nodel stage within the PSA nadir < 0.008 ng/ml group (P=0.0107). For this reason, postoperative follow-up using ultra-sensitive PSA is considered to be of value, since the use of high-sensitivity PSA to confirm a reduction to below postoperative measurement threshold value (PSA nadir < 0.008 ng/ml) may avert administering unnecessary additional treatment, regardless of pathological reccurrence factors.
Furubayashi N, Negishi T, Kashiwagi E, Hirata Y, Taguchi K, Hasegawa Y, Nakamura M. Are you the author?
Department of Urology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan; Department of Pathology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan; Gengen-do Urological Clinic, Usa 879-0471, Japan.
Reference: Mol Clin Oncol. 2014 Sep;2(5):851-857.